VALLEY COTTAGE, N.Y., July 20 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (Nasdaq: XTLB; TASE: XTL) announces the results of its Annual General Meeting ("AGM") and Extraordinary General Meeting ("EGM") held earlier today.
The outcome of the AGM was as follows: all of the resolutions passed and the existing Directors were reappointed.
The outcome of the EGM was as follows: resolution 4 was passed; resolutions 1, 2, 3 and 5 did not pass.
ABOUT XTL BIOPHARMACEUTICALS LTD.
XTL Biopharmaceuticals Ltd. ("XTL") is engaged in the development of therapeutics for the treatment of diabetic neuropathic pain and HCV. XTL is developing Bicifadine, a serotonin and norepinephrine reuptake inhibitor, for the treatment of diabetic neuropathic pain, which is currently in a Phase 2b study. XTL has out-licensed its novel pre-clinical HCV small molecule inhibitor program. XTL also has an active in-licensing and acquisition program designed to identify and acquire additional drug candidates. XTL is publicly traded on the NASDAQ and Tel-Aviv Stock Exchanges (Nasdaq: XTLB; TASE: XTL).
SOURCE XTL Biopharmaceuticals Ltd.
For further information: Ron Bentsur of XTL Biopharmaceuticals Ltd., Chief Executive Officer, +1-(845)-267-0707 ext. 225/ First Call Analyst:
© PR Newswire
